These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 2960639)

  • 21. Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
    Gurbel PA; Anderson RD; MacCord CS; Scott H; Serebruany V; Herzog WR
    Coron Artery Dis; 1994 Nov; 5(11):929-36. PubMed ID: 7719525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
    Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
    Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) and urokinase in acute myocardial infarct: intermediate results of the G.A.U.S. study (German Activator Urokinase Study)].
    Neuhaus KL; Tebbe U; Gottwik M; Weber MA; Feuerer W; Niederer W; Haerer W; Praetorius F; Grosser KD; Huhmann W
    Klin Wochenschr; 1988; 66 Suppl 12():102-8. PubMed ID: 3126339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The obsession with primary angioplasty.
    Melandri G
    Circulation; 2003 Dec; 108(23):e162. PubMed ID: 14662697
    [No Abstract]   [Full Text] [Related]  

  • 25. [The prevention of reocclusion after thrombolysis in acute myocardial infarct: is tissue-type plasminogen activator really superior to streptokinase?].
    Negrini M
    G Ital Cardiol; 1995 Apr; 25(4):511-5. PubMed ID: 7677921
    [No Abstract]   [Full Text] [Related]  

  • 26. [Advantages of immediate coronary dilatation after thrombolysis using tissue-type plasminogen activator in acute myocardial infarction. A European Cooperative Group trial].
    Vahanian A
    Arch Mal Coeur Vaiss; 1988 May; 81 Spec No():39-43. PubMed ID: 2973300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [PTCR, PTCA for the treatment in patients with acute myocardial infarction].
    Nobuyoshi M
    Nihon Naika Gakkai Zasshi; 1992 Aug; 81(8):1218-24. PubMed ID: 1431462
    [No Abstract]   [Full Text] [Related]  

  • 28. Coronary thrombolysis with tissue-type plasminogen activator: an overview.
    Van de Werf F; Collen D
    Eur Heart J; 1985 Nov; 6(11):902-4. PubMed ID: 3935445
    [No Abstract]   [Full Text] [Related]  

  • 29. Case history: successful thrombolytic therapy in a patient with acute myocardial infarction.
    Sait YR
    Heart Lung; 1988 Nov; 17(6 Pt 2):782-6. PubMed ID: 3142824
    [No Abstract]   [Full Text] [Related]  

  • 30. Primary angioplasty with routine stenting compared with thrombolytic therapy in elderly patients with acute myocardial infarction.
    Goldenberg I; Matetzky S; Halkin A; Roth A; Di Segni E; Freimark D; Elian D; Agranat O; Har Zahav Y; Guetta V; Hod H
    Am Heart J; 2003 May; 145(5):862-7. PubMed ID: 12766745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Anaphylactoid reaction during administration of tissue plasminogen activator (t-PA)].
    Cannas S; De Leo A; Marzari A
    G Ital Cardiol; 1997 Mar; 27(3):278-80. PubMed ID: 9244730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tissue plasminogen activator: an update.
    Myears DW; Ludbrook PA
    Compr Ther; 1989 Apr; 15(4):3-9. PubMed ID: 2495884
    [No Abstract]   [Full Text] [Related]  

  • 33. TIMI II and the role of angioplasty in acute myocardial infarction.
    Guerci AD; Ross RS
    N Engl J Med; 1989 Mar; 320(10):663-5. PubMed ID: 2521918
    [No Abstract]   [Full Text] [Related]  

  • 34. New developments in the treatment of acute myocardial infarction (III).
    Papapietro SE; Arciniegas JG; Cooper TB; Walls D; Carroll P; Simpson MT; Hess RG; Stanley AW; MacLean WA
    Ala Med; 1987 Mar; 56(9):20-3. PubMed ID: 2953218
    [No Abstract]   [Full Text] [Related]  

  • 35. [Thrombolysis following myocardial infarct: benefits are clarified].
    Michel D
    Fortschr Med; 1989 Jan; 107(3):14-5. PubMed ID: 2493412
    [No Abstract]   [Full Text] [Related]  

  • 36. [GISSI 2; the beginning of the end or the end of the beginning for tissue plasminogen activator in acute myocardial infarct?].
    Verheugt FW
    Ned Tijdschr Geneeskd; 1990 Sep; 134(35):1711-2. PubMed ID: 2120596
    [No Abstract]   [Full Text] [Related]  

  • 37. Thrombolysis and angioplasty in acute myocardial infarction.
    N Engl J Med; 1988 Mar; 318(9):576-9. PubMed ID: 2963215
    [No Abstract]   [Full Text] [Related]  

  • 38. Primary percutaneous coronary intervention.
    Gurewich V
    N Engl J Med; 2008 Jan; 358(4):431-2; author reply 432-3. PubMed ID: 18219753
    [No Abstract]   [Full Text] [Related]  

  • 39. t-PA therapy in acute myocardial infarction.
    Giebel RA; Pavey SS; Bryant PP
    J Emerg Nurs; 1988; 14(4):206-13. PubMed ID: 3137387
    [No Abstract]   [Full Text] [Related]  

  • 40. Do we need to intervene after thrombolysis in acute myocardial infarction?
    Sleight P
    Circulation; 1990 May; 81(5):1707-9. PubMed ID: 2110038
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.